January 23, 2020
Two years ago, 20Sense published an infographic describing four levels of PSP.18 Since that time, manufacturers have redoubled their efforts to reach levels 3 and 4. In collaboration with payers, patients and PSP providers, they are exploring opportunities to generate actionable data from their PSPs, including data to support outcomes-based reimbursement agreements.19 Patient data generated by PSPs—such as disease scores, safety, and adherence patterns—yields unparalleled insights into a treatment’s value, enabling stakeholders to make informed decisions about treatment, reimbursement and strategy.20
Basic PSP programs work well. Advancing through the levels makes them work even better. Higher-level PSPs yield a greater ROI and, above all, greater value to patients.
References:
18 - Optimize Your Operations: Take your PSP to the Next Level. 20Sense, January 15, 2018. https://www.20sense.ca/issue-2-biosimilars-and-patient-support-a-musthave-combination/2018/1/15/biosimilars-and-patient-support-a-must-have-combination-kf3s2
19 - RWE and OBA Working Group. 2019 Research and Outputs. November 25, 2019. https://static1.squarespace.com/static/58fd16af1b631b1afffae9e0/t/5dd9fd27b53adb35ea83ac32/1574567208259/2019_RWE_OBA_WorkingGroup_ExecSummary.pdf
20 - Insight Series: Value of Patient Support Programs for Specialty Medications in Canada. Innomar Strategies. May 17, 2018. https://www.innomar-strategies.com/insights/insight-series-value-of-patient-support-programs